As a shareholder I would expect that a partner will be chosen who can offer prexisting marketing and logistics channels.... And has the people and resources to introduce Vitro Gro on a Global level....
There will be a strong need to not only market the product globally... But to also have operatives out there who train and teach how to best use Vitro Gro...
IMO TIS's role is not to go alone... They don't have the people the time or the knowledge to do so.... They have produced a game changing product... And hired someone else to negotiate a commercial deal.... Soon it will be over to the big pharma's to turn it into cash... And for TIS holders to kick back and enjoy a percentage of that....
TIS should continue in R&D and stick to managing the rights of use to Vitro Gro and ensuring the best deals possible for Shareholders...
The only capital TIS require now is for the finalisation of Vitro Gro and the approvals in Europe and then the USA... A partner will take care of the rest...
Ive said this before but... The commercial deals are where it all ends... If the Pharma's dont chase this... Then we can assume that the product may not be as strong as we hope it is...
Alternatively if the Pharma's do chase it... IMO It will confirm a potential takeover of a multibillion dollar wound care market...
Remember the market is forward looking... TIS could garner a billion dollar market cap on the right news... Without even turning a cent...
Cheers...
Add to My Watchlist
What is My Watchlist?